The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality in systemic sclerosis, marked by complex immunopathogenic mechanisms and progressive fibrosis. Recent advances have illuminated key cellular players as T cells, macrophages, dendritic cell...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-08-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/17534666251366023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331463794720768 |
|---|---|
| author | Bohdana Doskaliuk Liubomyr Zaiats Nazar Sahan Yuliya Fedorchenko Olga Antymys Roman Yatsyshyn |
| author_facet | Bohdana Doskaliuk Liubomyr Zaiats Nazar Sahan Yuliya Fedorchenko Olga Antymys Roman Yatsyshyn |
| author_sort | Bohdana Doskaliuk |
| collection | DOAJ |
| description | Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality in systemic sclerosis, marked by complex immunopathogenic mechanisms and progressive fibrosis. Recent advances have illuminated key cellular players as T cells, macrophages, dendritic cells, and profibrotic mediators such as TGF-β, PDGF, and CTGF, alongside emerging roles for epigenetic reprogramming in sustaining fibroblast activation. This narrative review synthesizes current understanding of immune-fibrotic crosstalk and critically evaluates both established therapies (e.g., mycophenolate mofetil, nintedanib, tocilizumab, and rituximab) and novel targeted approaches. Particular attention is given to emerging immunomodulatory, antifibrotic, and cell-based therapies, including CAR-T and mesenchymal stem cell treatments, as well as the potential of epigenetic modulators repurposed from oncology. By bridging basic science and clinical practice, this review outlines the evolving therapeutic landscape of SSc-ILD and highlights opportunities for future research and personalized intervention. |
| format | Article |
| id | doaj-art-54053f103cf64f228b4af416c58fdbfd |
| institution | Kabale University |
| issn | 1753-4666 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Respiratory Disease |
| spelling | doaj-art-54053f103cf64f228b4af416c58fdbfd2025-08-20T03:46:34ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46662025-08-011910.1177/17534666251366023The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventionsBohdana DoskaliukLiubomyr ZaiatsNazar SahanYuliya FedorchenkoOlga AntymysRoman YatsyshynSystemic sclerosis-associated interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality in systemic sclerosis, marked by complex immunopathogenic mechanisms and progressive fibrosis. Recent advances have illuminated key cellular players as T cells, macrophages, dendritic cells, and profibrotic mediators such as TGF-β, PDGF, and CTGF, alongside emerging roles for epigenetic reprogramming in sustaining fibroblast activation. This narrative review synthesizes current understanding of immune-fibrotic crosstalk and critically evaluates both established therapies (e.g., mycophenolate mofetil, nintedanib, tocilizumab, and rituximab) and novel targeted approaches. Particular attention is given to emerging immunomodulatory, antifibrotic, and cell-based therapies, including CAR-T and mesenchymal stem cell treatments, as well as the potential of epigenetic modulators repurposed from oncology. By bridging basic science and clinical practice, this review outlines the evolving therapeutic landscape of SSc-ILD and highlights opportunities for future research and personalized intervention.https://doi.org/10.1177/17534666251366023 |
| spellingShingle | Bohdana Doskaliuk Liubomyr Zaiats Nazar Sahan Yuliya Fedorchenko Olga Antymys Roman Yatsyshyn The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions Therapeutic Advances in Respiratory Disease |
| title | The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions |
| title_full | The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions |
| title_fullStr | The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions |
| title_full_unstemmed | The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions |
| title_short | The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions |
| title_sort | fibrosis puzzle of systemic sclerosis associated ild and the quest for targeted interventions |
| url | https://doi.org/10.1177/17534666251366023 |
| work_keys_str_mv | AT bohdanadoskaliuk thefibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT liubomyrzaiats thefibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT nazarsahan thefibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT yuliyafedorchenko thefibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT olgaantymys thefibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT romanyatsyshyn thefibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT bohdanadoskaliuk fibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT liubomyrzaiats fibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT nazarsahan fibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT yuliyafedorchenko fibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT olgaantymys fibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions AT romanyatsyshyn fibrosispuzzleofsystemicsclerosisassociatedildandthequestfortargetedinterventions |